
- /
- Supported exchanges
- / US
- / MIRM.NASDAQ
Mirum Pharmaceuticals Inc (MIRM NASDAQ) stock market data APIs
Mirum Pharmaceuticals Inc Financial Data Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Mirum Pharmaceuticals Inc data using free add-ons & libraries
Get Mirum Pharmaceuticals Inc Fundamental Data
Mirum Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 379 M
- EBITDA: -52 304 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mirum Pharmaceuticals Inc News

Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up
Biotech stock Mirum Pharmaceuticals has rocketed 236% since its IPO in 2019. Shares are near a buy point after earnings. Continue Reading View Comments


CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner
Nvidia partner CoreWeave stock has retreated from its all-time high and is carving a base that offers an entry at 166.63. Continue Reading View Comments

High Growth Tech Stocks In The US Market
Amidst a backdrop of fluctuating market sentiment, the S&P 500 and Nasdaq Composite have shown resilience by rebounding from early losses, driven by investor optimism around trade negotiations and rob...

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
It has been about a month since the last earnings report for Editas Medicine (EDIT). Shares have added about 40% in that time frame, outperforming the S&P 500. Will the recent positive trend continue...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.